CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
mosunetuzumab 与 CAR-T 细胞疗法在复发/难治性滤泡性淋巴瘤中的成本效果
英文原题：Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.
查看英文原题
Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向T细胞的疗法，包括mosunetuzumab（mosun）、阿基仑赛（axi-cel）和替沙妥司他（tisa-cel），已获FDA批准用于三线及以上复发/难治性滤泡性淋巴瘤（FL）。目前没有头对头临床试验数据可比较这些疗法的疗效。这些产品在给药方式、住院要求和毒性特征方面各不相同，影响治疗选择。我们从美国支付方角度建立覆盖1至10年的Markov模型，参数来自临床试验、健康效用和计费成本。10年基础情景分析显示，每名患者接受mosun比axi-cel多获得67,654美元净货币收益（NMB），比tisa-cel多获得111,709美元。这些发现提示，按每质量调整生命年支付意愿阈值15万美元计算，mosun具有成本效益。
展开英文摘要原文
T cell redirecting therapies, including mosunetuzumab (mosun), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel), are FDA-approved for relapsed refractory follicular lymphoma (FL) in the 3rd line and beyond. There's no head-to-head clinical trial data to compare their effectiveness. These products differ in administration, hospitalization requirements, and toxicity profiles, impacting therapy selection.
We developed a Markov model spanning one to 10 years from a US payer perspective, using parameters from clinical trials, quality utilities, and billing costs.
Our base case analysis over 10 years showed that mosun provided $67,654 more Net Monetary Benefit (NMB) per patient than axi-cel and $111,709 more than tisa-cel.
These findings suggest mosun is cost-effective at a $150,000 willingness-to-pay per QALY.
论文信息
- 作者
- Lin MH、Weiss J、Phillips TJ、Sano D、Carty SA、Wilcox R、Ghosh M、Ahmed I
- 第一作者单位
- School of Public Health, University of Michigan, Ann Arbor, MI, USA.United States
- 通讯作者单位
- Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.United States
- 期刊
- Leukemia & lymphoma2025 Oct
- 原文标识
- PubMed 40488632 · DOI 10.1080/10428194.2025.2506498